Contact Us   |   Print Page   |   Sign In   |   Join
News and Press: Member Organization News

Esperion Plans $150 Million Stock Offering, Stock Soars on News of Cholesterol Drug Trial

Thursday, March 19, 2015   (0 Comments)
Share |
From Crain's Detroit
By Tom Henderson

Following the release of positive results from human trials of its cholesterol drug this week, which sent its stock price rocketing in two days, Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR) has announced it intends a public offering of $150 million. Shares in the company opened Tuesday at $75.55 and closed on the good news at $99.60. They hit a high of $109.85 Wednesday before falling back to a close of $105.72. Impetus was added Wednesday when Bank of America Merrill Lynch…

[Read full article online]

Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership  ::  Legal